EXCITON TECHNOLOGIES RECEIVES HEALTH CANADA APPROVAL TO MARKET SILVER WOUND DRESSING

EDMONTON, Jan. 17 /CNW/ - Exciton Technologies Inc. today announced the Company has received Health Canada approval to market the exsalt^TM SD7 Wound Dressing within Canada. The dressing is a Class II medical device initially targeting the treatment of serious burns and chronic wounds. The exsalt^TM SD7 Wound Dressing incorporates Exciton's patented platform coating technology, which utilizes a unique form of silver as the active ingredient.

"This achievement represents a significant team effort and a strong belief in our product," stated Rod Precht, Exciton's President and Founder. "To date, our technologies have demonstrated superior attributes over other leading silver technologies, allowing us to offer effective products at a highly competitive price.  With the approval from Health Canada and FDA clearance back in 2009, we can now finalize our commercialization efforts to sell the exsalt^TM SD7 Wound Dressing throughout North America. Health Canada approval is a significant achievement, requiring stringent ISO 13485 medical device manufacturing certification prior to filing, and paves the way for regulatory approval in other countries."

The global wound care market was $14 billion in 2008 and is expected to exceed $17 billion by 2012. A recent resurgence in the use of silver dressings has been largely due to an increase in the number of antimicrobial-resistant organisms. With a long history of safety, silver continues to be the most promising antimicrobial treatment in a market segment expected to exceed $750 million by 2015.  Initial evaluations of the exsalt^TM SD7 Wound Dressing within the US last year have validated the performance of this next generation product within a rapidly growing market.

About exsalt™ SD7 Wound Dressing
The exsalt™ SD7 Wound Dressing is indicated for use on partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, and other acute or chronic wounds. The exsalt™ SD7 Wound Dressing maintains its broad spectrum antimicrobial activity for up to seven days.

About Exciton Technologies Inc.
Exciton Technologies Inc. is a privately held Alberta advanced materials research and development company focused on the creation of technologies for preventing and controlling infection. Currently our valuable portfolio of patentable platform technologies is based on the antimicrobial properties of silver. The Company's technologies offer next-generation and less expensive products, enabling the company to participate in many industries, including the wound care and disinfectant markets.

Forward-looking Statements
This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.

For further information:

Website:www.excitontech.com